Riley, Megan
Lambrelli, Dimitra
Graham, Sophie
Henry, Ouzama
Sutherland, Andrea
Schmidt, Alexander
Sawalhi-Leckenby, Nicola
Donaldson, Robert
Stoszek, Sonia K.
Article History
Received: 3 November 2021
Accepted: 9 May 2022
First Online: 1 June 2022
Declarations
:
: CPRD obtained ethics approval to receive and supply patient data for public health research (ExternalRef removed). The protocol of this retrospective observational cohort study was approved by the Independent Scientific Advisory Committee (ISAC) for research involving CPRD data (protocol no. 18_144RA) and has been made available to the journal reviewers. All methods were carried out in accordance with relevant guidelines and regulations. As per CPRD process (ExternalRef removed), no information that can identify a patient is ever sent to CPRD; CPRD never receives any patient identifiers from a GP practice such as patient name, address, NHS number, full date of birth or medical notes; and because a patient cannot be identified from data a GP practice sends to CPRD, ISAC does not require the GP practice to seek a patient’s consent to share data with CPRD. This study is based on data from the CPRD obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the National Health Service as part of their care and support. The interpretation and conclusions contained in this report are those of the authors alone.
: Not applicable.
: MR and OH are employees of the GSK group of companies (GSK). ASc, ASu, and SS were GSK employees at the time of the study. OH, ASc, and SS own GSK stocks or shares. DL, NSL, RD, and SG are salaried employees of Evidera, the consultancy company hired by GSK to perform this work. The authors declare no other financial or non-financial interests.